Slide 1: Investor Presentation Q3FY24
Investor Presentation Q3FY24 22-01-2024 1
Slide 2: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Q3FY24: Revenue up 14% YoY; Margin expansion by 220+ bps YoY
Q3FY24 : Revenue up by 14% YoY; Margin expansion by 220+ bps YoY KEY HIGHLIGHTS Global Revenue EBITDA Margin R&D Investment1 14% INR 1748 Cr (Reported) 24% INR 6,604 Cr (Reported) (YoY) 26.5% margin (YoY) 6.1% 10% 14% INR 1,720 Cr (Ex-QCIL) 25% of reported YoY INR 6,544 Cr (Ex-QCIL) 26.3% margin rev
Slide 4: Financial Performance – Q3FY24 (Ex-QCIL)
Financial Performance – Q3FY24 (Ex-QCIL) Revenues INR 6,544 Cr EBITDA INR 1,720 Cr Revenue1 Break-up Q3FY24 (Consolidated) API, 2% Others, 2% Actuals vs Q3 FY23 International (INR Cr) Markets, 11% Total Revenue from 6,544 14.2% Operations SAGA Excl EBITDA 1,720 24.9% QCIL, 12% EBITDA % 26.3% 230 bps
Slide 5: Healthy Cash position – Continued focus on building balance sheet strength
Healthy Cash position – Continued focus on building balance sheet strength INR Cr Total Debt1 Cash Balance2 Net Cash3 7,591 7,143 6,138 6,941 6,811 5,850 961 803 449 Jun'23 Sep'23 Dec'23 Jun'23 Sep'23 Dec'23 Jun'23 Sep'23 Dec'23 1. Total debt includes lease liabilities and working capital loan| 2. I
Slide 6: Cipla Q3FY24 – Current growth with promising future
Cipla Q3FY24 – Current growth with promising future 15th Consecutive quarter of Filed gSymbicort and one YoY growth in US other respiratory product in US India Rx – Chronic share Actor Pharma SA – improves by ~100 bps YoY to Competition Commission 60.3%1 approval received Healthy Net Cash of INR 7,1
Slide 7: One India: Consolidation of market leadership aided by growth
One India1 : Consolidation of market leadership aided by growth INR Cr One India business Q3 YoY revenue trend One India business TTM YoY revenue trend Ex-covid CAGR Ex-covid CAGR 13% 12% 2,859 2,560 2,297 10,706 1,967 9,566 8,496 Q 3 FY 2 1 Q 3 F Y 22 Q3 FY23 Q3 FY24 Branded Prescription Trade Gene
Slide 8: India Rx – Outpacing market growth backed by Chronic portfolio and Big Brands
India Rx – Outpacing market1 growth backed by Chronic portfolio and Big Brands Steady uptake in Chronic portfolio1 Rank IPM 8.3% 9.1% 3rd Overall Chronic 9.5% 2nd 11.1% Respiratory 5.1% 1st 11.3% Cardiac 8.8% 7th 11.1% Urology 12.1% 15.9% 2nd Market Growth Cipla Growth Ranks 1st in IPM1 Foracort Gai
Slide 9: One India: Digital initiatives accelerating offerings across Continuum of Care
One India : Digital initiatives accelerating offerings across ‘Continuum of Care’ Doctor Patients Distributors Study material Awareness campaigns Deepening connect Integrated omnichannel New ‘Inhalers Hain Sahi Film’ Ensure key product availability experience combining in-clinic achieved 40 Mi
Slide 10: 9MFY2024 Global Consumer Wellness Franchise
9MFY2024 Global Consumer Wellness Franchise One India Consumer brands in India Pain relief Nicotine Replacement Hydration Skin infection Cold & cough ~8% INR 1,034 Cr INR ~195 Cr INR 130+ Cr INR 141C`r INR 110+ Cr INR 90+ Cr INR ~80 Cr Contribution of Global Consumer franchise to overall revenues So
Slide 11: North America: Continuous growth trajectory backed by positive traction in key assets
North America: Continuous growth trajectory backed by positive traction in key assets 15th consecutive quarter of growth in revenue over previous year $ Mn 18% 229 230 222 204 195 179 160 155 150 141 143 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 11
Slide 12: North America: Base business grows keeping focus on future pipeline
North America: Base business grows keeping focus on future pipeline Key Business Highlights North America • Highest ever quarterly revenue at $230 Mn with a growth of 18% $ Mn YoY Q3 FY24 YoY • Lanreotide – Cipla has set a new benchmark in 505(b)2 market 230 share by getting to 20% market share • St
Slide 13: ANDA & NDA Portfolio & Pipeline (As on 31st Dec 2023)
ANDA & NDA Portfolio & Pipeline (As on 31st Dec 2023) 13 61 9 4 19 8 80 2 1 49 20 7 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs Cipla Ltd PEPFAR1 Invagen Partnered ANDAs/NDAs 163 30 80 273 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDAs &
Slide 14: SAGA: Steady growth across businesses
SAGA1: Steady growth across businesses ZAR Mn SA Private Q3 YOY- Growing at double digit CAGR South Africa CAGR 11% In secondary terms, strong demand 13 1,106 935 962 continues with overall South Africa 809 private growing faster than the market2 Positive traction in tender business Brands launc
Slide 15: Q3FY24: International Markets & API
Q3FY24 : International Markets & API International Markets API Revenue $ Mn Revenue $ Mn 93 18 90 13 Q3FY23 Q3FY24 Q3FY23 Q3FY24 15
Slide 16: ESG Update
ESG Update Progress on ESG : YTD Nov’2023 32% Renewable Energy in the energy mix vs 29% in YTD Nov-22 2.3% YoY reduction in absolute GHG emission for scope 1 (fuel based) and scope 2 1.8 % reduction in freshwater withdrawal 45.9% of water recycled and reused as percentage of water withdrawal against
Slide 17: Profit and Loss statement summary (Reported)
Profit and Loss statement summary (Reported) Q3 FY24 Q3 FY23 Particulars (INR Cr) (INR Cr) Rev enue from sale of products 6,506 5,730 Other operating income 98 80 Income from operations 6,604 5,810 Material cost 2,220 2,004 Employee benefits expense 1,068 949 Other expenses 1,569 1,450 Total expense
Slide 18: Balance Sheet
Balance Sheet Dec'23 Sep'23 Mar'23 Particulars (INR Cr.) (INR Cr.) (INR Cr.) Net tangible assets 5,847 5,725 5,740 Goodwill and other intangibles 4,280 4,464 4,514 Investments 562 561 573 Other non-current assets 389 364 352 Income tax assets (net) 369 346 531 Deferred tax assets (net) 273 346 293 I
Slide 19: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Ajinkya Pandharkar Investor.Relations@cipla.com Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.ci